Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Michel Peterschmitt, Nigel P.S. Crawford, Sebastiaan J.M. Gaemers, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 1, pp. 86-98
Open Access | Times Cited: 86

Showing 26-50 of 86 citing articles:

Astrocytes in ischemic stroke: Crosstalk in central nervous system and therapeutic potential
Jueling Liu, Yuying Guo, Yunsha Zhang, et al.
Neuropathology (2023) Vol. 44, Iss. 1, pp. 3-20
Closed Access | Times Cited: 11
Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)
Raphael Schiffmann, Eugen Mengel, Mary Wallace, et al.
Advances in Therapy (2024) Vol. 41, Iss. 7, pp. 2907-2923
Open Access | Times Cited: 4
Pipeline of Pharmacotherapy in Parkinson’s Disease
Florian Brugger, Stefan Hägele-Link
Cambridge University Press eBooks (2025), pp. 290-305
Closed Access
Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics
Li Li, Yanyan Zhang, Jyoti Sharma, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access
Progress and Challenges in the Treatment of Fabry Disease
Malte Lenders, Elise Raphaela Menke, Eva Brand
BioDrugs (2025)
Open Access
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
Michel Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Journal of Parkinson s Disease (2021) Vol. 12, Iss. 2, pp. 557-570
Open Access | Times Cited: 26
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease
Manoj Kumar, Manasa P. Srikanth, Michela Deleidi, et al.
Human Molecular Genetics (2023) Vol. 32, Iss. 11, pp. 1888-1900
Open Access | Times Cited: 10
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment inGBA-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
Fabiana Colucci, Micol Avenali, Rosa De Micco, et al.
BMJ Neurology Open (2023) Vol. 5, Iss. 2, pp. e000535-e000535
Open Access | Times Cited: 10
Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
M. A. Babcock, Zheng Jian-hong, Jessica Gail Shurr, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 6, pp. 696-709
Open Access | Times Cited: 3
Inhibitors of Glucosylceramide Synthase
James A. Shayman, Vania Hinkovska‐Galcheva, Liming Shu
Methods in molecular biology (2023), pp. 271-288
Closed Access | Times Cited: 9
Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson’s Disease
Rémi Kinet, Benjamin Dehay
Cells (2023) Vol. 12, Iss. 4, pp. 621-621
Open Access | Times Cited: 9
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
Catherine Viel, Jennifer Clarke, Can Kayatekin, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Fabry disease: current treatment and future perspective
Han‐Wook Yoo
Journal of Genetic Medicine (2023) Vol. 20, Iss. 1, pp. 6-14
Open Access | Times Cited: 7
Limitations and opportunities in the pharmacotherapy of ciliopathies
Max Duong Phu, Stefan Bross, Martin D. Burkhalter, et al.
Pharmacology & Therapeutics (2021) Vol. 225, pp. 107841-107841
Open Access | Times Cited: 17
Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore
Y. Tanaka, Masaki Seto, Keiko Kakegawa, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 4270-4290
Open Access | Times Cited: 11
The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies
Maurizio Pieroni, Michele Ciabatti, Francesca Graziani, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 6
Open Access | Times Cited: 11
Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases
Gregory Heller, Allison M. Bradbury, Mark S. Sands, et al.
Molecular Therapy (2022) Vol. 31, Iss. 1, pp. 7-23
Open Access | Times Cited: 11
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
Ronald T. Gansevoort, Ali Hariri, Pascal Minini, et al.
American Journal of Kidney Diseases (2022) Vol. 81, Iss. 5, pp. 517-527.e1
Open Access | Times Cited: 11
Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
Gabriel C. Baccam, Jian Xie, Xin Jin, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein
Alina Schidlitzki, Miloš Stanojlović, Céline Fournier, et al.
Movement Disorders (2023) Vol. 38, Iss. 6, pp. 1044-1055
Open Access | Times Cited: 6
Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma
Gianluca Bossù, Laura Pedretti, Lorenzo Bertolini, et al.
Children (2023) Vol. 10, Iss. 5, pp. 869-869
Open Access | Times Cited: 6
Cardiovascular Involvement in Fabry’s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management
Emanuele Monda, Luigi Falco, Giuseppe Palmiero, et al.
Cardiac failure review (2023) Vol. 9
Open Access | Times Cited: 6
Cardiac MRI in Fabry disease
Muhammad Umer, Dinesh Kalra
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access | Times Cited: 5
Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement
Anna Burban, Szymon Pucyło, Aleksandra Sikora, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13239-13239
Open Access | Times Cited: 5

Scroll to top